Ngomhlaka-22 Meyi 2025, i-Allist Pharmaceuticals yamemezela ukuthi umuthi wayo omusha i-Airuikai (Glecirasib Citrate Tablets), i-KRAS-G12C inhibitor, usuvunyelwe ngokusemthethweni ukuthi uqaliswe emakethe yi-National Medical Products Administration (NMPA). Ukuvunyelwa kuvumela i-Airuikai ukuthi isetshenziswe ekwelapheni iziguli ezindala ezine-KRAS®®G12C-mutated advanced non-small cell lung cancer (NSCLC) ezake zathola okungenani umugqa owodwa wokwelashwa okuhleliwe. Lokhu kuphawula okunye ukwelashwa okusha komdlavuza wamaphaphu okuvunyelwe i-Allist Pharmaceuticals, okunikeza inketho entsha yokwelapha iziguli ezine-KRASG12C-mutated non-small cell lung cancer (NSCLC) futhi kusiza ekwakheni kabusha isimo sokwelashwa salolu hlobo lomdlavuza okunzima ukuluphatha.
Ukuvunyelwa kusekelwe emiphumeleni evela ocwaningweni olubalulekile lweSigaba II lwengalo eyodwa oluhlola ukuphepha, ukubekezeleleka, kanye nokusebenza kahle kwe-Glecirasib monotherapy ezigulini ezinomdlavuza wamaphaphu ongeyona encane othuthukisiwe one-KRASG12Cmutations eziye zehluleka noma ezingabekezelelanga ukwelashwa okujwayelekile.
Imiphumela ibonise ukuthi iGoleresai iyasebenza futhi ibekezelelwa kahle. Kusukela ngomhlaka-28 Septhemba 2024, iziguli ze-NSCLC eziyi-119 zifakiwe ekuhlaziyweni. Izinga lokuphendula eliqinisekisiwe (i-cORR), njengoba lihlolwe yiKomidi Lokubuyekeza Elizimele (i-IRC), lalingu-49.6% (40.2%-59.0%), kanye nezinga lokulawula izifo (i-DCR) elingu-86.3% (78.7%-92.0%). Ubude besikhathi esimaphakathi sempendulo (i-DOR) babuyizinyanga ezingu-14.5 (izinyanga ezingu-9.6 kuya ku-akulinganiswe), ukusinda okumaphakathi okungenakho ukuqhubekela phambili (i-PFS) kwakungu-8.2 izinyanga (5.2–11.1), kanye nokusinda okumaphakathi okuphelele (i-OS) kwakungu-17.5 izinyanga (izinyanga ezingu-13.6 kuya ku-akulinganiswe).
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
Email：myimmnet@163.com
Isikhathi sokuthunyelwe: Meyi-27-2025